Pipecuronium bromide
Based on 1 Customer Validation
Pipecuronium bromide is a potent long-acting nondepolarizing steroidal neuromuscular blocking agent (NMBA), and a bisquaternary ammonium compound. Pipecuronium bromide is a powerful competitive nAChR antagonist with a Kd of 3.06 μM.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 52212-02-9
- Formula: C35H62Br2N4O4
- Molecular Weight:762.70
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Sugammadex has a high affinity for Pipecuronium bromide. As Pipecuronium bromide is about 6 to 7 times more potent than Rocuronium, fewer molecules are required to achieve a comparative blockade than in the case of Rocuronium[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Carboxymethylated γ-cyclodextrin shows efficient and complete reversal of the Pipecuronium bromide induced neuromuscular block in an ex vivo rat diaphragm experiment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 52212-02-9
-
Appearance Solid
-
Molecular Weight 762.70
-
Formula C35H62Br2N4O4
-
Color Off-white to yellow
-
SMILES
C[C@@]1([C@H]2OC(C)=O)[C@](C[C@@H]2N3CC[N+](C)(C)CC3)([H])[C@@](CC[C@]4([H])[C@@]5(C[C@H](N6CC[N+](C)(C)CC6)[C@@H](OC(C)=O)C4)C)([H])[C@]5([H])CC1.[Br-].[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 150 mg/mL (196.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (131.11 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tassonyi E, et al. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial. Anesth Analg. 2015 Aug;121(2):373-80. [Content Brief]
[2]. Tassonyi E, et al. Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial. Anesth Analg. 2018 Dec;127(6):1344-1350. [Content Brief]
[3]. Alánt O, et al. First clinical experience with a new neuromuscular blocker pipecurium bromide. Arzneimittelforschung. 1980;30(2a):374-9. [Content Brief]
[4]. Töröcsik A, et al. Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202(3):297-302. [Content Brief]
[5]. Kárpáti E, et al. Investigation of neuromuscular blocking agents at Richter Ltd. Acta Pharm Hung. 2002;72(1):37-48. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.3111 mL | 6.5557 mL | 13.1113 mL | 32.7783 mL |
| 5 mM | 0.2622 mL | 1.3111 mL | 2.6223 mL | 6.5557 mL | |
| 10 mM | 0.1311 mL | 0.6556 mL | 1.3111 mL | 3.2778 mL | |
| 15 mM | 0.0874 mL | 0.4370 mL | 0.8741 mL | 2.1852 mL | |
| 20 mM | 0.0656 mL | 0.3278 mL | 0.6556 mL | 1.6389 mL | |
| 25 mM | 0.0524 mL | 0.2622 mL | 0.5245 mL | 1.3111 mL | |
| 30 mM | 0.0437 mL | 0.2185 mL | 0.4370 mL | 1.0926 mL | |
| 40 mM | 0.0328 mL | 0.1639 mL | 0.3278 mL | 0.8195 mL | |
| 50 mM | 0.0262 mL | 0.1311 mL | 0.2622 mL | 0.6556 mL | |
| 60 mM | 0.0219 mL | 0.1093 mL | 0.2185 mL | 0.5463 mL | |
| 80 mM | 0.0164 mL | 0.0819 mL | 0.1639 mL | 0.4097 mL | |
| 100 mM | 0.0131 mL | 0.0656 mL | 0.1311 mL | 0.3278 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.